RANBP2 and cancer: This is essential due to the observed lack of correlation between the chemical sensitivity of amrubicin, a fully synthetic anthracycline anti-cancer agent and effective TopoII inhibitor, and the mRNA expression levels of RANBP2, TopoII-α, and TopoII-β genes.